Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Tumor Mutational Burden in Follicular Lymphoma Patients Treated with Immunochemotherapy

Marta Lafuente, Ramon Diez-Feijoo, Concepción Fernández-Rodríguez, Raquel Longarón, Lierni Fernández-Ibarrondo, Nieves Garcia-Gisbert, Marta García-Recio, Blanca Sanchez-Gonzalez, Sergio Pinzon, Joan Gibert, Laura Camacho, Luis Colomo, Antonio Gutierrez, Beatriz Bellosillo, Antonio Salar

Blood (2023) 142 (Supplement 1): 2989.

https://doi.org/10.1182/blood-2023-180622

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Fernando Martín Moro, Leyre Bento De Miguel, Juan Marquet Palomanes, Antonio Gutierrez, Antonio Diaz-Lopez, Jose M. Sanchez, Jose Antonio Garcia Vela, Antonio Salar, Raul Cordoba, Silvana Novelli, Maria J. Rodriguez-Salazar, Sonia González de Villambrosia, Raquel Del Campo, Hugo Daniel Luzardo Henriquez, Daniel Garcia, Juan-Manuel Sancho, Pau Abrisqueta, Alejandro Martín García-Sancho, Mariana Bastos-Oreiro

Blood (2022) 140 (Supplement 1): 779–781.

https://doi.org/10.1182/blood-2022-170854

Published: 2022

Journal Articles

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero Martínez, Javier López Jiménez, Paola Sandra Villafuerte Gutierrez, Ana Jimenez-Ubieto, Adolfo De La Fuente, Belén Navarro, Maria Stefania Infante, Raul Cordoba, Jaime Perez De Oteyza, Sonia González de Villambrosia, Raquel Del Campo, Daniel Garcia, Antonio Salar, Juan-Manuel Sancho

Blood (2022) 140 (Supplement 1): 3618–3619.

https://doi.org/10.1182/blood-2022-166027

Published: 2022

Journal Articles

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Blood (2022) 140 (Supplement 1): 9347–9349.

https://doi.org/10.1182/blood-2022-160073

Published: 2022

Journal Articles

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Blood (2022) 140 (Supplement 1): 9266–9268.

https://doi.org/10.1182/blood-2022-168552

Published: 2022

Journal Articles

Myelodysplastic Syndromes Presenting with Isolated Thrombocytopenia: A Less Aggressive Form of Presentation and with Better Prognosis

Marie Solange Flores-Moran, Leonor Arenillas, Ana Ferrer, Felix Lopez-Cadenas, Sara Garcia-Avila, Concepción Fernández, Antonio Salar, Xavier Calvo

Blood (2022) 140 (Supplement 1): 6960–6961.

https://doi.org/10.1182/blood-2022-167567

Published: 2022

Journal Articles

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Nieves Garcia-Gisbert, Brayan Merchan, Sara Garcia-Avila, Marta Salido, Concepción Fernández-Rodríguez, Joan Gibert, Lierni Fernández-Ibarrondo, Laura Camacho, Marta Lafuente, Raquel Longarón, Blanca Espinet, Patricia Vélez, Marcio M Andrade-Campos, Ramon M. Pujol, Leonor Arenillas, Xavier Calvo, Carles Besses, Antonio Salar, Beatriz Bellosillo

Blood (2021) 138 (Supplement 1): 2599.

https://doi.org/10.1182/blood-2021-148297

Published: 2021

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

Journal Articles

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Michael Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Krish Patel, Cyrus Khan, Nancy L. Bartlett, Gloria Iacoboni, Mark Hertzberg, Sirpa Leppä, Eric Van Den Neste, Monica Tani, Guillaume Cartron, Antonio Salar, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings

Blood (2021) 138 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2021-146845

Published: 2021

Journal Articles

Impact of the Use of Bendamustine Immediately before the Collection of Hematopoietic Stem Cells in Lymphoma. a Study By the Geltamo Group

Mariana Bastos-Oreiro, Javier Anguita, José Fernández, Ana Pilar Gonzalez, Raul Córdoba, Ana Isabel Jiminez Ubieto, Daniel Garcia, Carolina Martínez-Laperche, Valeria Delgado, Jose Garcia-Arroba, Antonio Salar, Juan-Manuel Sancho

Blood (2021) 138 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2021-150769

Published: 2021

Journal Articles

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Blood (2021) 138 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2021-147670

Published: 2021

Journal Articles

Multiple TET2 Mutations As a New Biological Clue for Differentiating Oligomonocytic Chronic Myelomonocytic Leukemia from Myelodysplastic Syndromes

Nieves Garcia-Gisbert, Leonor Arenillas, David Roman-Bravo, Juan José Rodríguez-Sevilla, Brayan Merchan, Sara Garcia-Avila, Concepción Fernández-Rodríguez, Joan Gibert, Antonio Salar, Beatriz Bellosillo, Ana Ferrer, Xavier Calvo

Blood (2021) 138 (Supplement 1): 1530.

https://doi.org/10.1182/blood-2021-152674

Published: 2021

Journal Articles

Clonal Dynamics of JAK2 V617F and Non-Driver Mutations in Polycythemia Vera and Essential Thrombocythemia Patients Receiving Hydroxyurea Therapy

Lierni Fernández-Ibarrondo, Joan Gibert, Concepción Fernández-Rodríguez, Laura Camacho, Anna Angona, Marcio Andrade, Nieves Garcia-Gisbert, Leonor Arenillas, Patricia Vélez, Raquel Longarón, Ramon Diez-Feijoo, Antonio Salar, Carles Besses, Beatriz Bellosillo

Blood (2021) 138 (Supplement 1): 3623.

https://doi.org/10.1182/blood-2021-150491

Published: 2021

Journal Articles

Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma

Peter Trask, Jaisson Bortolini, Shinya Rai, Antonio Salar, Miguel Canales, Dirk Klingbiel, Joana Parreira, Maud Deraet, Ekaterina Vorozheikina, Kai Hübel, Thomas Buchholz

Blood (2021) 138 (Supplement 1): 1345.

https://doi.org/10.1182/blood-2021-147911

Published: 2021

Journal Articles

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Marcio M Andrade-Campos, MD PhD, Lierni Fernández-Ibarrondo, Joan Gibert, PhD, Concepción Fernández, Brayan Merchan, MD, Nieves García Gisbert, BSc, Laura Camacho, Leonor Arenillas, MD PhD, Sara García Ávila, MD, Raquel Longarón, Antonio Salar, MD PhD, Carles Besses, MD PhD, Beatriz Bellosillo, PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142705

Published: 2020

Journal Articles

In Vitro Validation of Micro-RNAs (miRNAs) Associated to Treatment Failure in Diffuse Large B-Cell Lymphoma (DLBCL)

Adriana Sas, Leyre Bento, Josep Muncunill, Jordi Martínez-Serra, Teresa Ros, Víctor Asensio, Oliver Vögler, Antonio Salar, MD PhD, Antonia Sampol, MD, Regina Alemany, Antonio Gutierrez

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-141765

Published: 2020

Journal Articles

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Blood (2020) 135 (13): 996–1007.

https://doi.org/10.1182/blood.2019002395

Published: 2020

Includes: Supplemental data

Journal Articles

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Marcio M Andrade-Campos, MD PhD, Antonio Salar, MD PhD, Blanca Sanchez-Gonzalez, MD, Concepción Fernández-Rodríguez, Eva Gimeno, MD PhD, L Ruiz, Gabriel Piquer, Francesc Garcia-Pallarols, BSc, Natalia Papaleo, MD, Ivonne Vazquez, Lluís Colomo, MD PhD, Beatriz Bellosillo, PhD

Blood (2019) 134 (Supplement_1): 492.

https://doi.org/10.1182/blood-2019-131081

Published: 2019

NARROW

Prognostic Value of Tumor Mutational Burden in Follicular Lymphoma Patients Treated with Immunochemotherapy

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Myelodysplastic Syndromes Presenting with Isolated Thrombocytopenia: A Less Aggressive Form of Presentation and with Better Prognosis

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Impact of the Use of Bendamustine Immediately before the Collection of Hematopoietic Stem Cells in Lymphoma. a Study By the Geltamo Group

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Multiple TET2 Mutations As a New Biological Clue for Differentiating Oligomonocytic Chronic Myelomonocytic Leukemia from Myelodysplastic Syndromes

Clonal Dynamics of JAK2 V617F and Non-Driver Mutations in Polycythemia Vera and Essential Thrombocythemia Patients Receiving Hydroxyurea Therapy

Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

In Vitro Validation of Micro-RNAs (miRNAs) Associated to Treatment Failure in Diffuse Large B-Cell Lymphoma (DLBCL)

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only